The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
15-deoxy-Δ12,14-PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats
Open accessAbstract
IntroductionRheumatoid arthritis (RA) is a chronic, destructive inflammatory polyarticular joint disease, characterized by massive synovial proliferation and subintimal infiltration of inflammatory cells, along with angiogenesis (1, 2).The inflammation of RA results in the production of prostaglandins (PGs) E 2 , cytokines, and nitric oxide (1, 3).In particular, macrophage-derived cytokines such as TNF-α (4) and IL-1 (5), which are abundant in synovial tissues and fluid from patients with RA, are mitogens for synovial fibroblasts, as well as osteoclasts.Blocking of these cytokines inhibits the release of synovial production of other proinflammatory cytokines.This suggests that TNF-α and IL-1 are key proinflammatory molecules in cytokine cascade in RA.In fact, TNF-α receptor antagonists, neutralizing antibodies against TNF-α, and IL-1 receptor antagonist can control joint inflammation in most RA patients (6-8).Moreover, the formation of active inflamed pannus is thought to be critical for erosive disease and results in irreversible destruction of the cartilage and bone in affected joints.The mechanism responsible for synovial hyperplasia leading to pannus formation may be due to reduced apoptosis of inflam-matory cells and tumor-like synoviocytes (9, 10).Therefore, suppression of the production of inflammatory molecules and formation of hyperplastic synovium may be important targets of therapy for RA.Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcriptional factors that include receptors for steroids, thyroid hormone, vitamin D, and retinoic acid (11).PPAR binds to peroxisome proliferator responsive element (PPRE) as a heterodimer with the retinoic receptor (RXR), implying a role of 9-cis retinoic acid in the regulation of PPAR target genes (12, 13).To date, three mammalian PPAR subtypes have been isolated and termed PPAR-α, NUC1 (also known as PPAR-δ), and PPAR-γ (11, 14, 15).PPAR-α is highly expressed in the liver, heart, kidney, muscle, brown adipose tissue, and gut, which exhibit high carbolic rates of fatty acids (14, 16).PPAR-δ may be expressed ubiquitously, and its function is relatively unknown (17).Recent studies suggest that PPAR-δ may be a target for nonsteroidal anti-inflammatory drug-induced (NSAIDinduced) tumor suppression in colorectal tumors (18).PPAR-γ is expressed at high levels in adipose tissue and is a critical regulator of adipocyte differentiation (19).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Elliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Cited by
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
Self-citationProstaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
Anti-inflammatory lipid mediators and insights into the resolution of inflammation
Lawrence, T., Willoughby, D. A., & Gilroy, D. W. (2002) · Nature Reviews Immunology · doi:10.1038/nri915 · Cited by 862
Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.01.016 · Cited by 793
Inflammatory Resolution: new opportunities for drug discovery
Gilroy, D. W., Lawrence, T., Perretti, M., & Rossi, A. G. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1383 · Cited by 772
Possible new role for NF-κB in the resolution of inflammation
Lawrence, T., Gilroy, D. W., Colville-Nash, P. R., & Willoughby, D. A. (2001) · Nature Medicine · doi:10.1038/nm1201-1291 · Cited by 749
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Cellular Metabolism and Macrophage Functional Polarization
Zhu, L., Zhao, Q., Yang, T., Ding, W., & Zhao, Y. (2015) · International Reviews of Immunology · doi:10.3109/08830185.2014.969421 · Cited by 428
Makowski, L., Brittingham, K. C., Reynolds, J. M., Suttles, J., & Hotamisligil, G. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413788200 · Cited by 410
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Self-citation15d-PGJ2: The anti-inflammatory prostaglandin?
Scher, J. U., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.008 · Cited by 348
The role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337
Old and new generation lipid mediators in acute inflammation and resolution
Stables, M. J., & Gilroy, D. W. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.07.005 · Cited by 334
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Ameshima, S., Golpon, H., Cool, C. D., Chan, D., Vandivier, R. W., Gardai, S. J., Wick, M., Nemenoff, R. A., Geraci, M. W., & Voelkel, N. F. (2003) · Circulation Research · doi:10.1161/01.res.0000073585.50092.14 · Cited by 292
Diab, A., Deng, C., Smith, J. D., Hussain, R. Z., Phanavanh, B., Lovett-Racke, A. E., Drew, P. D., & Racke, M. K. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2508 · Cited by 291
Inflammatory pathways in atherosclerosis and acute coronary syndromes
Plutzky, J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01924-5 · Cited by 279
Subbaramaiah, K., Lin, D. T., Hart, J. C., & Dannenberg, A. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007237200 · Cited by 275
RetractedHedgehog signaling plays a conserved role in inhibiting fat formation
Suh, J. M., Gao, X., McKay, J., McKay, R., Salo, Z., & Graff, J. M. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.012 · Cited by 271
Sundararajan, S., Gamboa, J. L., Victor, N. A., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266
Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis
Abramson, S. B., Attur, M., Amin, A. R., & Clancy, R. (2001) · Current Rheumatology Reports · doi:10.1007/s11926-001-0069-3 · Cited by 261
The Anti-Inflammatory Effects of Prostaglandins
Scher, J. U., & Pillinger, M. H. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31819aaa76 · Cited by 259
Natarajan, C., & Bright, J. J. (2002) · Genes & Immunity · doi:10.1038/sj.gene.6363832 · Cited by 208
Ghosh, A. K., Bhattacharyya, S., Lakos, G., Chen, S., Mori, Y., & Varga, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20104 · Cited by 201
Liu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation
Weinberg, J. B. (2000) · Immunologic Research · doi:10.1385/ir:22:2-3:319 · Cited by 121
Zhang-Gandhi, C. X., & Drew, P. D. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.007 · Cited by 117
Insulin Signaling in Arthritis
Tripolino, C., Ciaffi, J., Pucino, V., Ruscitti, P., van Leeuwen, N., Borghi, C., Giacomelli, R., Meliconi, R., & Ursini, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672519 · Cited by 46
Metadata
- Authors
- Kawahito, Y., Kondo, M., Tsubouchi, Y., Hashiramoto, A., Bishop-Bailey, D., Inoue, K.-I., Kohno, M., Yamada, R., Hla, T., & Sano, H.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-07-15
- Volume
- 106
- Issue
- 2
- Pages
- 189-197
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2124371647
- Cited by
- 377
- References
- 54
- FWCI
- 21.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.